Diasome Pharmaceuticals
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10000 Cedar Ave Ste 6, Cleveland, Ohio, ...Phone Number
(216) 444-7110Website
www.diasome.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Diasome Pharmaceuticals
Diasome specializes in targeted hepatic drug delivery, focusing on improving treatments for diabetes, obesity, and metabolic dysfunction through its innovative HDV platform. This first-in-class technology directs therapeutics to the portal-hepatic region, enhancing the efficacy of metabolic therapies by restoring liver-driven control of glucose and lipids. The company is committed to advancing next-generation therapies, with a research pipeline that includes insulin, serotonin, and GLP-1 to address unmet needs in metabolic health. Led by a team of renowned researchers and clinicians, Diasome aims to bridge the gap between scientific discovery and real-world patient impact.Explore more
Diasome Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Diasome Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Diasome Pharmaceuticals has new funding data
Click to see if Diasome Pharmaceuticals had a recent Job posting/layoffs
Check if Diasome Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Diasome Pharmaceuticals
Check out if Diasome Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Diasome Pharmaceuticals launches new products
Earning: See what the market has to say on Diasome Pharmaceuticals recently announced quarterly report
Diasome Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Diasome Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Diasome Pharmaceuticals
Compare insights from companies similar to Diasome Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.8M
11-50
Private
$40M
1996
CB
Chaim BrickmanSenior Medical Director, Clinical Development & Pharmacovigilance
Company Profile Activity
Activity Insights
Diasome Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Diasome Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Diasome Pharmaceuticals.
Diasome Pharmaceuticals financials insights
Gather financial insights about Diasome Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$4.3M
Diasome Pharmaceuticals Tech Stack
A closer look at the technologies used by Diasome Pharmaceuticals
See more technologies
Diasome Pharmaceuticals News & Media
Diasome to Present Phase 2b Results from OPTI-2 Trial Evaluating HDV-Insulin Lispro in Type 1 Diabetes at ADA 86th Scientific Sessions
Data from randomized, double-blind study in 226 adults to be presented as an oral abstract Data from randomized, double-blind study in 226 adults to be presented as an oral abstractDiasome Pharmaceuticals Launches Groundbreaking OPTI-2 Phase 2b Trial in Type 1 Diabetes
CLEVELAND, OH, UNITED STATES, February 29, 2024 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel liver targeting drug platform, announced today the initiation of the OPTI-2 Phase 2b …Diasome Pharmaceuticals Announces First Closing of Series C Financing Round
Diasome Secures Series C Funding with Eli Lilly Participation CLEVELAND, OH, USA, December 7, 2023 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform …Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions
Diasome Pharmaceuticals, Inc., a global leader in the development of innovative therapeutics for diabetes, is pleased to announce that the company's Chief
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Diasome Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Diasome specializes in targeted hepatic drug delivery, focusing on improving treatments for diabetes, obesity, and metabolic dysfunction through its innovative HDV platform. This first-in-class technology directs therapeutics to the portal-hepatic region, enhancing the efficacy of metabolic therapies by restoring liver-driven control of glucose and... Read More
